HSIC

Business profile & competitive position

Henry Schein, Inc. (HSIC) sits in the Healthcare sector under the Medical - Distribution industry classification. That label describes a business model built around moving medical products through distribution channels rather than developing patented pharmaceuticals or medical devices. As a distributor, Henry Schein typically earns thin profits per dollar of sales but tries to offset that with scale, inventory breadth, and logistics efficiency.

The numbers support that reading. The company carries a $10.0 billion market cap and reports a net margin of just 3.0%. A margin that narrow is characteristic of distribution businesses where pricing is competitive and value is created through turnover and cost control rather than large per-unit markups. Return on equity, however, comes in at 12.4%, which is meaningfully higher than the net margin. That ROE gap usually signals respectable capital turnover and some financial leverage rather than outsized pricing power. The stock’s beta of 0.81 is also below the market average, suggesting investors treat the shares as relatively defensive even though the underlying business is not a high-margin compounder. In short, Henry Schein’s competitive posture appears to rest on scale and operational execution more than on a wide, high-margin economic moat.

Financial posture

Henry Schein trades at a P/E of 25.5 against a 3.0% net margin and a 12.4% ROE. Those figures are worth unpacking together. A 25.5 multiple implies the market is paying roughly $25.50 for every $1 of trailing earnings, which translates to an earnings yield of about 3.9%. That is a notable premium over the 3.0% net margin, meaning the valuation is not simply pricing the company as a no-growth distributor. For that multiple to be justified by fundamentals alone, the market must be expecting some combination of revenue growth, margin recovery, or capital-return improvements.

By itself, the 12.4% ROE is solid for a low-margin distributor, but it is not exceptional relative to many healthcare companies that benefit from patent protection or recurring high-margin revenue. The $10.0 billion market cap places Henry Schein firmly in the mid-cap range, with enough liquidity for institutions but still a size where execution and guidance can move the stock. The beta of 0.81 confirms lower systematic risk than the broader market, which is typical for defensive Healthcare names. Overall, the financial posture reads as a quality distribution business carrying a valuation that already embeds decent expectations.

Macro & geopolitical exposure

The Medical - Distribution classification carries a set of macro and geopolitical sensitivities that are broader than company-specific fundamentals. Distributors sit between manufacturers and end users, so their results can be affected by supply-chain disruptions, freight and logistics costs, and inventory availability. Any tariffs or trade restrictions on imported medical products, personal protective equipment, or healthcare consumables can influence input costs and, depending on contract structures, pressure gross margins.

Currency is another relevant factor. A global distributor that sources or sells across borders can see reported results swing with dollar strength or weakness. On the demand side, the business is tied to patient volumes: more dental visits, physician office visits, and surgical procedures generally translate into higher product consumption. Reimbursement rules, Medicare and Medicaid policy changes, and broader healthcare regulation can indirectly shape provider purchasing patterns. Finally, because distribution is a working-capital-intensive business, interest-rate levels matter for inventory financing costs. These are industry-level exposures; they do not predict Henry Schein’s next quarter, but they frame the macro forces that can move the stock.

Recent developments

Henry Schein has drawn fresh media attention around its second-quarter 2026 report and the stock’s price action. On August 4, 2026, the company released Q2 results and hosted its earnings call; both the full transcript on seekingalpha.com and the call highlights on marketbeat.com were published the same day. On August 5, 2026, zacks.com ran the headline “Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?,” flagging the post-earnings momentum. Two days after the report, on August 6, 2026, zacks.com followed with “HSIC or SAUHY: Which Is the Better Value Stock Right Now?,” placing Henry Schein in a direct value comparison with a peer.

The timing is notable: the stock reached a fresh high shortly after reporting Q2 earnings, yet the current price of $88.13 sits above a 50-day exponential moving average of $83.57 and an RSI of 60.5. That RSI reading is elevated but not in traditionally overbought territory, which fits the “fresh high” narrative without implying an extreme technical condition. The cluster of headlines suggests the market is actively reassessing Henry Schein’s relative value after the latest print.

Earnings behavior & post-earnings drift

Henry Schein’s earnings track record over the past eight quarters shows a 75% beat rate, with six beats out of eight reports and an average earnings surprise of 2.9%. On the surface that is a solid fundamental record. But the price behavior after reports tells a more complicated story. Across those same eight quarters, the average 5-day move following earnings was -2.76%, classified as a “down” post-earnings drift. In other words, even when the company has beaten expectations, the market has often sold the news over the following week.

The last four reports illustrate the dynamic clearly. On August 4, 2026, HSIC reported actual EPS of $1.27 against an estimate of $1.24, a 2.4% beat; the stock rose 0.54% the next day and was flat over the next five trading days. On May 5, 2026, the company delivered $1.32 versus $1.20, a 10% positive surprise, yet the stock fell 2.6% the next session and dropped 6.75% over the following five days. On February 24, 2026, EPS of $1.34 beat the $1.30 estimate by 3.1%, but the next-day move was -1.73% and the five-day drift was -3.77%. The only recent exception was the November 4, 2025 report, where $1.38 versus $1.27, an 8.7% beat, produced a 0.56% next-day gain and a positive 2.25% five-day drift.

The next scheduled report is November 3, 2026, before the market open, with the market's real expectation currently anchored at a consensus EPS estimate of $1.34. Traders watching the setup should note that beating estimates has been the base case historically, but the stock’s average tendency has been to drift lower once the headline settles.

For readers who want to go further, the full institutional verdict—including detailed multi-quarter surprise trends, volume patterns around the last several reports, and broader analyst sentiment—provides a deeper lens on how the market may price the next earnings release.